PMID- 32565844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1710-1484 (Print)
IS  - 1710-1492 (Electronic)
IS  - 1710-1484 (Linking)
VI  - 16
DP  - 2020
TI  - Efficacy of omalizumab in children, adolescents, and adults with severe allergic 
      asthma: a systematic review, meta-analysis, and call for new trials using current 
      guidelines for assessment of severe asthma.
PG  - 49
LID - 10.1186/s13223-020-00442-0 [doi]
LID - 49
AB  - BACKGROUND: Omalizumab is approved for treating severe allergic asthma from age 
      6, but the definition of severe asthma including a systematic assessment to rule 
      out difficult-to-treat asthma has changed since the drug was approved in 2003. 
      METHODS: We conducted a systematic review and meta-analysis of two critical 
      (exacerbation rate, oral corticosteroid (OCS) treatment) and eight important 
      clinical outcomes in children, adolescents and adults, and specifically searched 
      papers for systematic assessment of severe asthma. RESULTS: Adults: seven studies 
      (n = 2159) ascertaining exacerbation rate showing a 37% (95% CI 21-50) reduction 
      in favor of omalizumab, larger than the pre-specified minimal clinically 
      important difference (MCID) of 25%. Only one open-label study (n = 82) was 
      identified assessing the percentage of patients experiencing reduction of 
      OCS-maintenance treatment showing a significantly greater decrease in the 
      omalizumab group (- 45% vs. + 18.3%, p = 0.002). Children and adolescents: four 
      studies (n = 1551) reported data on exacerbations (no meta-analysis conducted), 
      showed overall improvements in exacerbation rate and some passed MCID. No OCS 
      studies were identified. No included studies provided systematic assessment of 
      severe asthma according to current guidelines. CONCLUSIONS: Omalizumab provides 
      clinically relevant improvements in exacerbation rate among children, 
      adolescents, and adults and in OCS-reduction among adults. New studies 
      incorporating a guideline-approached definition of severe asthma are warranted.
CI  - (c) The Author(s) 2020.
FAU - Henriksen, Daniel P
AU  - Henriksen DP
AUID- ORCID: 0000-0003-1303-6195
AD  - Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 
      Odense, Denmark. GRID: grid.7143.1. ISNI: 0000 0004 0512 5013
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of 
      Southern Denmark, Odense, Denmark. GRID: grid.10825.3e. ISNI: 0000 0001 0728 0170
FAU - Bodtger, Uffe
AU  - Bodtger U
AD  - Department of Respiratory Medicine, Naestved Hospital, Naestved, Denmark. GRID: 
      grid.416369.f. ISNI: 0000 0004 0631 4668
AD  - Department of Medicine, Zealand University Hospital, Roskilde, Denmark. GRID: 
      grid.476266.7
FAU - Sidenius, Kirsten
AU  - Sidenius K
AD  - Allergi og Lungeklinikken Helsingor, Helsingor, Denmark.
FAU - Maltbaek, Niels
AU  - Maltbaek N
AD  - Department of Medicine, Zealand University Hospital, Roskilde, Denmark. GRID: 
      grid.476266.7
FAU - Pedersen, Lars
AU  - Pedersen L
AD  - Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark. 
      GRID: grid.411702.1. ISNI: 0000 0000 9350 8874
FAU - Madsen, Hanne
AU  - Madsen H
AD  - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark. 
      GRID: grid.7143.1. ISNI: 0000 0004 0512 5013
FAU - Andersson, Ehm A
AU  - Andersson EA
AD  - The Danish Medicines Council Secretariat, Copenhagen, Denmark.
FAU - Norgaard, Ole
AU  - Norgaard O
AD  - The Danish Medicines Council Secretariat, Copenhagen, Denmark.
FAU - Madsen, Louise K
AU  - Madsen LK
AD  - The Danish Medicines Council Secretariat, Copenhagen, Denmark.
FAU - Chawes, Bo L
AU  - Chawes BL
AD  - COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and 
      Gentofte University Hospital, University of Copenhagen, Ledreborg Alle 34, 
      Gentofte, 2820 Copenhagen, Denmark. GRID: grid.5254.6. ISNI: 0000 0001 0674 042X
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200618
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian 
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC7302157
OTO - NOTNLM
OT  - Anti-IgE
OT  - Omalizumab
OT  - Severe asthma
OT  - Systematic review
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
PMCR- 2020/06/18
CRDT- 2020/06/23 06:00
PHST- 2019/11/16 00:00 [received]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
PHST- 2020/06/18 00:00 [pmc-release]
AID - 442 [pii]
AID - 10.1186/s13223-020-00442-0 [doi]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2020 Jun 18;16:49. doi: 10.1186/s13223-020-00442-0. 
      eCollection 2020.